News25/Ratings4
News · 26 weeks42-87%
2025-10-262026-04-19
Mix2790d
- SEC Filings16(59%)
- Insider9(33%)
- Other2(7%)
Latest news
25 items- SECSEC Form S-3 filed by Cingulate Inc.S-3 - Cingulate Inc. (0001862150) (Filer)
- SECCingulate Inc. filed SEC Form 8-K: Leadership Update8-K - Cingulate Inc. (0001862150) (Filer)
- SECSEC Form 424B3 filed by Cingulate Inc.424B3 - Cingulate Inc. (0001862150) (Filer)
- SECSEC Form EFFECT filed by Cingulate Inc.EFFECT - Cingulate Inc. (0001862150) (Filer)
- SECSEC Form EFFECT filed by Cingulate Inc.EFFECT - Cingulate Inc. (0001862150) (Filer)
- SECCingulate Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Submission of Matters to a Vote of Security Holders8-K - Cingulate Inc. (0001862150) (Filer)
- SECSEC Form 424B3 filed by Cingulate Inc.424B3 - Cingulate Inc. (0001862150) (Filer)
- SECAmendment: SEC Form S-3/A filed by Cingulate Inc.S-3/A - Cingulate Inc. (0001862150) (Filer)
- SECSEC Form DEFA14A filed by Cingulate Inc.DEFA14A - Cingulate Inc. (0001862150) (Filer)
- SECSEC Form 10-K filed by Cingulate Inc.10-K - Cingulate Inc. (0001862150) (Filer)
- SECCingulate Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits8-K - Cingulate Inc. (0001862150) (Filer)
- PRCingulate Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Operational HighlightsKANSAS CITY, Kan., March 18, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to develop a pipeline of next-generation products, today reported financial results for the quarter ended December 31, 2025, and provided a corporate update. Highlights include recent U.S. and European patent developments, the closing of a $12 million private investment, and the acceptance of a New Drug Application (NDA) for its lead candidate, CTx-1301 (dexmethylphenidate HCl). Cingulate CEO Shane J. Schaffer stated, "Cingulate delivered on key inflection points throughout 2025 and this continues i
- INSIDEREVP and CSO Silva Raul R. was granted 4,526 shares and covered exercise/tax liability with 1,828 shares, increasing direct ownership by 139% to 4,645 units (SEC Form 4)4 - Cingulate Inc. (0001862150) (Issuer)
- INSIDEREVP, CLO and CCO Patel Nilay Dahyabhai was granted 5,475 shares and covered exercise/tax liability with 2,086 shares (SEC Form 4)4 - Cingulate Inc. (0001862150) (Issuer)
- INSIDERChief Executive Officer Schaffer Shane J. was granted 6,862 shares and covered exercise/tax liability with 2,959 shares, increasing direct ownership by 2,256% to 4,076 units (SEC Form 4)4 - Cingulate Inc. (0001862150) (Issuer)
- INSIDEREVP and CFO Callahan Jennifer L. was granted 15,329 shares and covered exercise/tax liability with 6,427 shares, increasing direct ownership by 176% to 13,961 units (SEC Form 4)4 - Cingulate Inc. (0001862150) (Issuer)
- INSIDEREVP and Chief Medical Officer Brams Matthew covered exercise/tax liability with 1,025 shares and was granted 4,526 shares, increasing direct ownership by 75% to 8,157 units (SEC Form 4)4 - Cingulate Inc. (0001862150) (Issuer)
- SECSEC Form DEF 14A filed by Cingulate Inc.DEF 14A - Cingulate Inc. (0001862150) (Filer)
- SECSEC Form PRE 14A filed by Cingulate Inc.PRE 14A - Cingulate Inc. (0001862150) (Filer)
- SECCingulate Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Cingulate Inc. (0001862150) (Filer)
- PRCingulate Announces the Closing of a $12 Million Private Placement Priced At-the-Market Under Nasdaq RulesKANSAS CITY, Kan., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company advancing next-generation treatments for ADHD and other CNS disorders, today announced the successful closing of a $12 million private investment in public equity (PIPE) financing, led by certain affiliates of Falcon Creek Capital Advisor LLC ("Falcon Creek Capital"). "This long-term financing from life science–focused institutional investors represents strong validation of our strategy, our technology, and the significant commercial opportunity ahead. The transaction included insider participation underscoring our confidence in the value we are building and our commitment to sta
- INSIDERSVP and CFO Callahan Jennifer L. bought $24,515 worth of shares (4,864 units at $5.04), increasing direct ownership by 2,494% to 5,059 units (SEC Form 4)4 - Cingulate Inc. (0001862150) (Issuer)
- INSIDERChief Executive Officer Schaffer Shane J. bought $34,317 worth of shares (6,809 units at $5.04) (SEC Form 4)4 - Cingulate Inc. (0001862150) (Issuer)
- INSIDERDirector Werth Peter J. bought $98,053 worth of shares (19,455 units at $5.04) (SEC Form 4)4 - Cingulate Inc. (0001862150) (Issuer)
- INSIDEREVP and Chief Medical Officer Brams Matthew bought $9,808 worth of shares (1,946 units at $5.04), increasing direct ownership by 72% to 4,656 units (SEC Form 4)4 - Cingulate Inc. (0001862150) (Issuer)